Earlier Menopause Linked to Accelerated Multimorbidity Progression: UK Biobank Multi-State Analysis Reveals Critical Windows for Preventive Intervention
Posted innews OB/GYN & Women's Health Public Health

Earlier Menopause Linked to Accelerated Multimorbidity Progression: UK Biobank Multi-State Analysis Reveals Critical Windows for Preventive Intervention

A large UK Biobank cohort study of 121,017 postmenopausal women reveals that earlier menopause significantly increases risks of multimorbidity progression, with women experiencing premature menopause facing 32% higher risk of developing first chronic disease and 22% higher risk of progressing to multimorbidity compared to those with menopause after age 50.
Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management
Posted inClinical Updates news OB/GYN & Women's Health

Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management

Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2b/3 trials with added benefits on sleep and quality of life.
Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile
Posted innews OB/GYN & Women's Health

Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile

OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean difference of −1.6 vs placebo (P < .001); numerical advantages persisted through 50–52 weeks with no signal for hepatotoxicity or endometrial hyperplasia.
Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review
Posted inClinical Updates news OB/GYN & Women's Health Specialties

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone therapy duration, global experiences, breast cancer management, dementia risk, and personalized hormone therapy safety.